Table 4.
Adverse events of special interest – infections
| Preferred Term | NNS/CANDLE (N = 5) n (%) |
SAVI (N = 3) n (%) |
AGS (N = 1) n (%) |
Total (N = 9) n (%) |
|---|---|---|---|---|
| Patients ≥ 1 TEAE | 3 (60.0) | 2 (66.7) | 1 (100.0) | 6 (66.7) |
| Upper respiratory tract infection | 1 (20.0) | 1 (33.3) | 0 (0.0) | 2 (22.2) |
| Atypical mycobacterial infection | 0 | 1 (33.3) | 0 (0.0) | 1 (11.1) |
| BK virus infection | 1 (20.0) | 0 | 0 (0.0) | 1 (11.1) |
| Bronchopulmonary aspergillosis | 0 (0.0) | 1 (33.3) | 0 (0.0) | 1 (11.1) |
| Conjunctivitis | 0 (0.0) | 1 (33.3) | 0 (0.0) | 1 (11.1) |
| Cytomegalovirus chorioretinitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Folliculitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Localized infection | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Periodontitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Pharyngitis | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (11.1) |
| Pneumocystis jirovecii pneumonia | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Pneumonia cytomegaloviral | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Tinea capitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
AGS Aicardi-Goutières syndrome, n number of patients with at least one adverse event per event type, NNS/CANDLE Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, SAVI STING-associated vasculopathy with onset during infancy, STING stimulator of interferon genes, TEAE treatment-emergent adverse event